Hennion & Walsh Asset Management Inc. Purchases 72,037 Shares of Grifols, S.A. $GRFS

Hennion & Walsh Asset Management Inc. grew its position in Grifols, S.A. (NASDAQ:GRFS) by 13.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 592,173 shares of the biotechnology company’s stock after purchasing an additional 72,037 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.09% of Grifols worth $4,193,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Grifols by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,212 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Grifols by 36.0% during the second quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,842 shares in the last quarter. Allworth Financial LP lifted its holdings in Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,096 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in Grifols by 50.3% in the first quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,998 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GRFS shares. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings cut Grifols from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Finally, Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Stock Up 1.4%

Shares of Grifols stock opened at $8.05 on Tuesday. The firm has a market cap of $5.48 billion, a PE ratio of 42.37, a P/E/G ratio of 0.29 and a beta of 0.67. The business’s 50 day simple moving average is $7.51 and its 200 day simple moving average is $8.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37. Grifols, S.A. has a 52-week low of $6.96 and a 52-week high of $10.84.

Grifols Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were issued a $0.0945 dividend. The ex-dividend date was Thursday, July 2nd. Grifols’s dividend payout ratio (DPR) is 115.79%.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.